Diagnostic criteria of cancer nutrition related status
Yu Kaiying, Liu Lihui, Shi Hanping
Beijing Shijitan Hospital, Capital Medical University/Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, China
Abstract:Nutrition-related conditions (NRC) mainly refer to diseases associated with nutrition or nutrition related therapies. NRC includes malnutrition (undernutrition), sarcopenia, asthenia, weight loss, over weight, fat, micronutrient abnormality and refeeding syndrome. This article mainly introducesdiagnostic criteria of the most common nutritional status in cancer patients: malnutrition, cachexia, sarcopenia, and weight loss. Malnutrition was diagnosed by weight, BMI and Assessment Scale. The methods include subjective global assessment (SGA), mini nutritional assessment (MNA), and patient-generated subjective global assessment (PG-SGA). Cachexia was diagnosed by weight, skeletal muscle index and BMI. Sarcopenia was mainly diagnosed by muscle mass, strength and physical activity. Weight loss was mainly diagnosed by the loss rate whose points are the amount, the time, and the components of loss. Malnutrition includes mild malnutrition, moderate malnutrition and severe malnutrition. Cachexia includes pre-cachexia, cachexia and bad cachexia. Sarcopenia includes primary sarcopenia and secondary sarcopenia. Weight loss includes 0 to 4 grades. The diagnosis of tumor nutrition related status is helpful to clarify the nutritional status of tumor patients.
于恺英,刘俐惠,石汉平. 肿瘤营养相关状况诊断标准[J]. 肿瘤代谢与营养电子杂志, 2020, 7(1): 1-6.
Yu Kaiying, Liu Lihui, Shi Hanping. Diagnostic criteria of cancer nutrition related status. Electron J Metab Nutr Cancer, 2020, 7(1): 1-6.
1.Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49-64.
2.Cederholm T, Bosaeus I, Barazzoni R, et al. Diagnostic criteria for malnutrition-An ESPEN Consensus Statement. Clin Nutr. 2015;34(3):335-340.
3.Sobotka L. Basics in clinical nutrition. 4th ed. Galen;2012.
4.Song C, Cao J, Zhang F, et al.Nutritional risk assessment by Scored Patient-Generated Subjective Global Assessment associated with demographic characteristics in 23,904 common malignant tumors patients. Nutr Cancer. 2019:71(1):50-60
5.石汉平,凌文华,李薇. 肿瘤营养学. 北京:人民卫生出版社, 2012.
6.石汉平,张晓伟,李薇,等. WS/T555—2017 肿瘤患者主观整体营养评估.北京:中国标准出版社,2017.
7.石汉平,张晓伟,李薇,等. 肿瘤患者主观整体营养评估.WS/T 555-2017.
8.Cederholm T, Jensen GL, Correia MITD, et al. GLIM core leadership committee; GLIM working group.GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community.Clin Nutr. 2019;38(1):1-9.
9.Jensen GL, Cederholm T, Correia MITD, et al.GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. JPEN J Parenter Enteral Nutr. 2019;43(1):32-40.
10.Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 2011, 12(5):489-495.
11.Baracos VE, Mazurak VC, Bhullar AS. Cancer cachexia is defined by an ongoing loss of skeletal muscle mass.Ann Palliat Med. 2019;8(1):3-12.
12.Yang QJ, Zhao JR, Hao J, et al. Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(1):71-85.
13.Zhou T, Wang B, Liu H, et al. Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients.J Cachexia Sarcopenia Muscle. 2018;9(2):306-314.
14.Alfonso J, Cruz-Jentoft, Jean Pierre Baeyens,et al. Bauer. Sarcopenia: european consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing. 2010; 39(4):412-423.
15.Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
16.Sayer AA, Syddall H, Martin H, et al. The developmental origins of sarcopenia.J Nutr Health Aging. 2008;12(7):427-432.
17.Sayer AA, Syddall HE, Martin HJ, et al. Falls, sarcopenia, and growth in early life: findings from the Hertfordshire cohort study.Am J Epidemiol. 2006;164(7):665-671.
18.陈梅梅, 石汉平. 肌肉功能评价方法. 肿瘤代谢与营养电子杂志. 2014;1(3):49-52.
19.Mohd Nawi SN, Khow KS, Lim WS, et al. Screening tools for sarcopenia in community-dwellers: a scoping review. Ann Acad Med Singapore. 2019;48(7):201-216.
20.Zhuang CL, Huang DD, Pang WY, et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort. Medicine (Baltimore). 2016;95(13):e3164.
21.Huang DD, Zhou CJ, Wang SL, et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer. Surgery. 2017;161(3):680-693.
22.Chen XY, Li B, Ma BW, et al. Sarcopenia is an effective prognostic indicator of postoperative outcomes in laparoscopic-assisted gastrectomy.Eur J Surg Oncol. 2019;45(6):1092-1098.
23.Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-495.
24.Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90-99.
25.Martin L. Diagnostic criteria for cancer cachexia: data versus dogma.Curr Opin Clin Nutr Metab Care. 2016;19(3):188-198.
26.Crawford J. What are the criteria for response to cachexia treatment? Ann Palliat Med. 2019;8(1):43-49.